SOLID-TIMI 52

SOLID-TIMI 52 was a randomized, double-blind, placebo-controlled trial to assess the efficacy of darapladib, a novel Lp-PLA2 inhibitor, when added to standard of care in high-risk patients stabilized after ACS.

MAIN RESULTS:
Rivaroxaban in patients with a recent acute coronary syndrome

N Engl J Med. 2012 Jan 5;366(1):9-19.

PRESENTATIONS

TIMI 52 Slides
SOLID Ceramides (Gencer AHA 2019)
A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients with Cardiometabolic Disease (Patel, AHA 2020)

OTHER PUBLICATIONS

Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J. 2011 Oct;162(4):613-619.e1.

Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events. Cardiol Ther. 2013 Dec; 2(2): 125–134.

Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. J Am Heart Assoc. 2017 Jan 11;6(1):e004332.

Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017 Mar 28;69(12):1549-1559. 

Interleukin-6 And The Risk Of Adverse Outcomes In Patients After An Acute Coronary Syndrome: Observations From The SOLID-TIMI 52 Trial. J Am Heart Assoc. 2017 Oct 24;6(10):e005637.

Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome. Eur J Prev Cardiol. 2018 May;25(8):830-838.

Metabolic Syndrome And The Risk Of Adverse Cardiovascular Events After An Acute Coronary Syndrome: Insights From SOLID-TIMI 52 Trial. Eur J Prev Cardiol. 2018 May;25(8):830-838.

Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018 Jun 1;3(6):473-480.

Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome. J Am Heart Assoc. 2018 Oct 16;7(20):e009077.

Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 Nov 7;39(42):3810-3820.

Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2019 Dec 17;74(24):3013-3022.

Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwaa143. Published: 29 December 2020.

Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 Feb 16;143(7):685-695. doi: 10.1161/CIRCULATIONAHA.120.052339. 

Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. Eur J Prev Cardiol. 2020 Dec 29:zwaa143. doi: 10.1093/eurjpc/zwaa143..